Bg pattern

MONKASTA 4 mg CHEWABLE TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MONKASTA 4 mg CHEWABLE TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Monkasta 4 mg Chewable Tablets EFG

For Children from 2 to 5 Years

montelukast

Read all of this leaflet carefully before you start giving this medicine to your child, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for your child only. Do not give it to others, even if they have the same symptoms as your child, as it may harm them.
  • If your child experiences any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Monkasta and what is it used for
  2. What you need to know before your child takes Monkasta
  3. How to take Monkasta
  4. Possible side effects
  5. Storage of Monkasta
  6. Contents of the pack and further information

1. What is Monkasta and what is it used for

What is Monkasta

Monkasta is a leukotriene receptor antagonist that blocks substances called leukotrienes.

How Monkasta Works

Leukotrienes cause narrowing and swelling of the airways in the lungs. By blocking leukotrienes, Monkasta improves asthma symptoms and helps control asthma.

When Should Monkasta be Used

Your doctor has prescribed Monkasta to treat your child's asthma and prevent asthma symptoms during the day and night.

  • Monkasta is used for the treatment of patients between 2 and 5 years of age who are not adequately controlled with their medication and need additional treatment.
  • Monkasta is also used as an alternative treatment to inhaled corticosteroids in patients between 2 and 5 years of age who have not recently taken oral corticosteroids for the treatment of their asthma and have demonstrated that they are unable to use inhaled corticosteroids.
  • Monkasta also helps prevent narrowing of the airways caused by exercise in patients 2 years of age and older.

Depending on your child's symptoms and the severity of their asthma, your doctor will determine how to use Monkasta.

What is Asthma?

Asthma is a chronic disease.

Asthma includes:

  • difficulty breathing due to narrowing of the airways. This narrowing of the airways worsens and improves in response to various diseases.
  • airways that are sensitive and react to many things, such as cigarette smoke, pollen, cold air, or exercise.
  • swelling (inflammation) of the inner layer of the airways.

Asthma symptoms include: Cough, wheezing, and chest congestion.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before giving Monkasta to your child

Tell your doctor about any allergy or medical problem your child has now or has had.

Do not give Monkasta to your child

  • if your child is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).

Warnings and Precautions

Consult your doctor or pharmacist before giving Monkasta to your child

  • If your child's asthma or breathing worsens, tell your doctor immediately.
  • Monkasta oral is not indicated for the treatment of acute asthma attacks. If an attack occurs, follow the instructions given by your doctor to your child. Always keep your child's rescue inhaler with them for asthma attacks.
  • It is essential that your child takes all asthma medications prescribed by their doctor. Monkasta should not be used instead of other asthma medications prescribed by your doctor for your child.
  • If your child is being treated with asthma medications, be aware that if they develop a combination of symptoms such as flu-like illness, tingling or numbness of arms or legs, worsening of lung symptoms, and/or skin rash, they should consult their doctor.

Children and Adolescents

Do not give this medicine to children under 2 years of age.

For pediatric patients under 18 years of age, other formulations of this medicine are available based on the age range.

Taking Monkasta with Other Medicines

Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines, including those obtained without a prescription.

Some medicines may affect how Monkasta works, or Monkasta may affect how other medicines work.

Before taking Monkasta, tell your doctor if your child is taking the following medicines:

  • phenobarbital (used to treat epilepsy),
  • phenytoin (used to treat epilepsy),
  • rifampicin (used to treat tuberculosis and some other infections).

Taking Monkasta with Food and Drinks

Monkasta 4 mg chewable tablets should not be taken with food; they should be taken at least 1 hour before or 2 hours after food.

Pregnancy and Breastfeeding

This subsection is not applicable to Monkasta 4 mg chewable tablets, as their use is indicated in children between 2 and 5 years of age.

Driving and Using Machines

This subsection is not applicable to Monkasta 4 mg chewable tablets, as their use is indicated in children between 2 and 5 years of age. However, the following information is important for the active substance, montelukast.

Monkasta is not expected to affect your child's ability to drive a car or operate machinery. However, individual responses to the medicine may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with Monkasta may affect the patient's ability to drive or operate machinery.

Monkasta Contains Aspartame and Sodium

This medicine contains 1.2 mg of aspartame in each chewable tablet. Aspartame is a source of phenylalanine that may be harmful to your child if they have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it properly.

This medicine contains less than 1 mmol of sodium (23 mg) per chewable tablet, which is essentially "sodium-free".

3. How to Take Monkasta

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist for your child. In case of doubt, consult your doctor or pharmacist again.

  • This medicine should be administered to children under adult supervision. For children who have problems taking a chewable tablet, an oral granule formulation is available.
  • Your child should only take one Monkasta chewable tablet once a day, as prescribed by their doctor.
  • It should be taken even when you or your child do not have symptoms or when they have an acute asthma attack.

Use in Children from 2 to 5 Years of Age:

The recommended dose is one 4 mg chewable tablet at night.

If your child is taking Monkasta, ensure they do not take any other medicine that contains the same active substance, montelukast.

This medicine should be taken orally.

The tablets should be chewed before swallowing.

Monkasta 4 mg chewable tablets should not be taken with food; they should be taken at least 1 hour before or 2 hours after food.

If Your Child Takes More Monkasta Than They Should

Seek help from your child's doctor immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 652 04 20, indicating the medicine and the amount ingested.

In most cases of overdose, no side effects were reported. The symptoms that occurred most frequently in overdose in children and adults were abdominal pain, drowsiness, thirst, headache, vomiting, and hyperactivity.

If You Forget to Give Monkasta to Your Child

Try to give Monkasta as prescribed. However, if your child misses a dose, just resume the usual routine of one chewable tablet once a day.

Do not give a double dose to make up for missed doses.

If Your Child Stops Taking Monkasta

Monkasta can only treat your child's asthma if they continue taking it.

It is essential that your child continues taking this medicine for as long as their doctor prescribes it. It will help control your child's asthma.

If you have any further questions about the use of this medicine, ask your child's doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible Side Effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical trials conducted with Monkasta 4 mg chewable tablets, the side effects related to the administration of the medicine and reported most frequently (may affect up to 1 in 10 patients) were:

  • abdominal pain,
  • thirst.

Additionally, the following side effect was reported in clinical trials with montelukast 10 mg film-coated tablets and 5 mg chewable tablets:

  • headache.

These side effects were generally mild and occurred with a higher frequency in patients treated with montelukast than with placebo (a pill that does not contain the active substance).

Serious Side Effects

Talk to Your Child's Doctor Immediatelyif you notice any of the following side effects, which may be serious and for which your child may need urgent medical treatment.

Uncommon: may affect up to 1 in 100 people

  • allergic reactions including swelling of the face, lips, tongue, and/or throat that can cause difficulty breathing or swallowing,
  • behavior and mood changes: agitation, including aggressive behavior or hostility, depression,
  • seizures.

Rare: may affect up to 1 in 1,000 people

  • increased tendency to bleeding,
  • tremor,
  • palpitations.

Very Rare: may affect up to 1 in 10,000 people

  • combination of symptoms such as flu-like illness, tingling or numbness of arms and legs, worsening of lung symptoms, and/or skin rash (Churg-Strauss syndrome) (see Section 2),
  • low platelet count in blood,
  • behavior and mood changes: hallucinations, disorientation, suicidal thoughts and actions,
  • swelling (inflammation) of the lungs,
  • severe skin reactions (erythema multiforme) that can occur without warning,
  • inflammation of the liver (hepatitis).

Other Side Effects Have Been Reported While the Medicine Has Been on the Market

Very Common: may affect more than 1 in 10 people

  • upper respiratory tract infection.

Common: may affect up to 1 in 10 people

  • diarrhea, nausea, vomiting,
  • skin rash,
  • fever,
  • liver enzymes elevated.

Uncommon: may affect up to 1 in 100 people

  • behavior and mood changes: sleep disturbances, including nightmares, sleep problems, sleepwalking, irritability, feeling anxious, restlessness,
  • dizziness, drowsiness, tingling/numbness,
  • nosebleed,
  • dry mouth, indigestion,
  • bruising, itching, hives,
  • joint or muscle pain, muscle cramps,
  • bedwetting in children,
  • weakness/tiredness, malaise, swelling.

Rare: may affect up to 1 in 1,000 people

  • behavior and mood changes: attention disturbance, memory disturbance, uncontrolled movements of the muscles.

Very Rare: may affect up to 1 in 10,000 people

  • painful red lumps under the skin, most frequently on the shins (erythema nodosum),
  • behavior and mood changes: obsessive-compulsive symptoms,
  • stuttering.

Reporting of Side Effects

If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Monkasta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date that appears on the blister and on the carton after EXP. The expiry date is the last day of the month indicated.

Keep in the original package to protect from light.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for proper disposal. This will help protect the environment.

6. Contents of the Pack and Further Information

Composition of Monkasta

  • The active substance is montelukast.

Each chewable tablet contains 4 mg of montelukast (as montelukast sodium).

  • The other ingredients are mannitol (E421), microcrystalline cellulose, sodium croscarmellose, hydroxypropyl cellulose, aspartame (E951), red iron oxide (E172), black cherry flavor (also contains glycerol triacetate (E1518)), and magnesium stearate (see section 2 "Monkasta 4 mg contains aspartame and sodium").

Appearance of the Product and Contents of the Pack

The tablets are pink, speckled, round, slightly biconvex, with bisected edges and engraved with "4" on one side.

Available in boxes of 7, 10, 14, 20, 28, 30, 49, 50, 56, 84, 90, 98, 100, 140, or 200 chewable tablets in blisters.

Marketing Authorisation Holder

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

KRKA-POLSKA Sp. z o.o., ul. Równolegla 5, 02-235 Warsaw, Poland

You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:

KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Member State

Medicine Name

Austria

Montelukast Krka 4 mg Chewable Tablets

Belgium

Montelukast Krka 4 mg Chewable Tablets

Bulgaria

Монтелукаст Крка 4 мг жевателни таблетки

Cyprus

MONTELUKAST KRKA

Denmark

Montelukast Krka

Slovakia

Monkasta 4 mg žuvacie tablety

Spain

Monkasta 4 mg Comprimidos Masticables EFG

Estonia

MONKASTA

Finland

Montelukast Krka 4 mg Chewable Tablets

France

MONTELUKAST KRKA 4, Comprimé à Croquer

Hungary

Monalux 4 mg Rágótabletta

Ireland

Montelukast 4 mg Chewable Tablets

Italy

Monkasta

Latvia

Monkasta 4 mg Košlajamas Tabletes

Lithuania

Monkasta 4 mg Kramtomosios Tabletes

Norway

Montelukast Krka 4 mg Tyggetabletter

Netherlands

Montelukast Krka 4 mg Kauwtabletten

Poland

Monkasta

Portugal

Montelucaste KRKA 4 mg Comprimidos para Mastigar

Czech Republic

MONKASTA

Romania

Monkasta 4 mg Comprimido Masticabil

Sweden

Montelukast Krka 4 mg Tuggtablett

United Kingdom (Northern Ireland)

Montelukast 4 mg Chewable Tablets

Date of Last Revision of this Leaflet: February 2024

"Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/"

Online doctors for MONKASTA 4 mg CHEWABLE TABLETS

Discuss questions about MONKASTA 4 mg CHEWABLE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for MONKASTA 4 mg CHEWABLE TABLETS?
MONKASTA 4 mg CHEWABLE TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in MONKASTA 4 mg CHEWABLE TABLETS?
The active ingredient in MONKASTA 4 mg CHEWABLE TABLETS is montelukast. This information helps identify medicines with the same composition but different brand names.
How much does MONKASTA 4 mg CHEWABLE TABLETS cost in pharmacies?
The average pharmacy price for MONKASTA 4 mg CHEWABLE TABLETS is around 16.84 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures MONKASTA 4 mg CHEWABLE TABLETS?
MONKASTA 4 mg CHEWABLE TABLETS is manufactured by Krka D.D. Novo Mesto. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of MONKASTA 4 mg CHEWABLE TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MONKASTA 4 mg CHEWABLE TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to MONKASTA 4 mg CHEWABLE TABLETS?
Other medicines with the same active substance (montelukast) include MONKASTA 10 mg FILM-COATED TABLETS, MONKASTA 5 mg CHEWABLE TABLETS, MONTELUKAST ACCORD 10 mg FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media